FrancophonIA/ELRC3.0 huggingface dataset:
English: Gastrointestin al disorders nausea vomiting , diarrhoea, abdominal pain, dysphagia, stomatitis, constipation, dyspepsia, anorexia, throat irritation abdominal enlargement gastro-intesti nal perforation7
Croatian: Poremećaji probavnog sustava mučnina povraćanje, proljev, bol u abdomenu, disfagija, stomatitis, konstipacija, dispepsija, anoreksija, iritacija grla povećanje abdomena gastrointestinalna perforacija7
English: EFS - Event Free Survival TTP - Time to progression or death PFS - Progression-Free Survival TTF - Time to Treatment Failure OS rates - survival rates at the time of the analyses
Croatian: Event Free Survival) TTP - vrijeme do progresije bolesti ili smrti (engl.
English: b) Chronic lymphocytic leukaemia
Croatian: b) kronične limfocitne leukemije
English: The recommended dose of Blitzima in combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory patients with follicular lymphoma is: 375 mg/m2 body surface area per cycle, for up to 8 cycles.
Croatian: Preporučena doza lijeka Blitzima u kombinaciji s kemoterapijom za uvodno liječenje bolesnika s prethodno neliječenim ili relapsirajućim/refraktornim folikularnim limfomom iznosi 375 mg/m površine tijela po ciklusu, tijekom najviše 8 ciklusa.
English: What you need to know before you use Blitzima Do not take Blitzima if:
Croatian: Što morate znati prije nego počnete primati lijek Blitzima
English: Initial treatment, bulky disease, weekly for 4 doses In pooled data from three trials, 39 patients with relapsed or chemoresistant, bulky disease (single lesion ≥ 10 cm in diameter), low grade or follicular B cell NHL received 375 mg/m2 of rituximab as intravenous infusion weekly for four doses.
Croatian: Početno liječenje, prošireni tumor, jedanput tjedno tijekom 4 tjedna U objedinjenim podacima iz tri ispitivanja 39 bolesnika s relapsirajućim ili kemorezistentnim proširenim ne-Hodgkinovim limfomom (promjer jedne lezije ≥ 10 cm) niskog stupnja malignosti ili folikularnim B-staničnim ne-Hodgkinovim limfomom je primilo rituksimab u dozi od 375 mg/m putem intravenske infuzije jedanput tjedno tijekom četiri tjedna.
English: See the Blitzima package leaflet for more information.
Croatian: Za više informacija pročitajte uputu o lijeku Blitzima.
English: Mean change from baseline: Modified total sharp score Erosion score Joint space narrowing score Proportion of patients with no radiographic change
Croatian: Srednja vrijednost promjene od početnih vrijednosti: Prilagođen ukupan rezultat na Sharpovoj ljestvici Stupanj erozije
English: % SF‐36 PHS MCID Mean change in SF‐36 MHS
Croatian: Srednja vrijednost promjene SF-36 PHS % bolesnika sa SF-36 PHS MCID
English: Physician information
Croatian: Informacije za liječnike
English: Rituximab maintenance treatment consisted of a single infusion of rituximab at 375 mg/m2 body surface area given every 2 months until disease progression or for a maximum period of two years.
Croatian: Terapija održavanja rituksimabom sastojala se od jedne infuzije rituksimaba u dozi od 375 mg/m tjelesne površine svaka 2 mjeseca do progresije bolesti ili najdulje dvije godine.
English: EGIS Praha, spol.
Croatian: Stamullen, Co.
English: Rituximab maintenance treatment consisted of a single infusion of rituximab at 375 mg/m2 body surface area given every 3 months until disease progression or for a maximum period of two years.
Croatian: Terapija održavanja rituksimabom sastojala se od primjene jedne infuzije rituksimaba u dozi od 375 mg/m tjelesne površine svaka tri mjeseca do progresije bolesti ili najdulje dvije godine.
English: In a randomised, open-label trial, a total of 399 previously untreated elderly patients (age 60 to 80 years) with diffuse large B cell lymphoma received standard CHOP chemotherapy (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 up to a maximum of 2 mg on day 1, and prednisolone 40 mg/m2/day on days 1-5) every 3 weeks for eight cycles, or rituximab 375 mg/m2 plus CHOP (R-CHOP).
Croatian: U randomiziranom otvorenom ispitivanju ukupno je 399 prethodno neliječenih starijih bolesnika (u dobi od 60 do 80 godina) s difuznim limfomom velikih B-stanica primalo standardnu CHOP kemoterapiju (ciklofosfamid 750 mg/m2, doksorubicin 50 mg/m2, vinkristin 1,4 mg/m do najviše 2 mg prvog dana liječenja te prednizolon 40 mg/m2/dan od prvog do petog dana liječenja) svaka 3 tjedna u osam ciklusa liječenja, ili rituksimab u dozi od 375 mg/m u kombinaciji s CHOP kemoterapijom (R-CHOP).
English: Investigation s decreased
Croatian: Pretrage smanjene razine
English: Table 13 Radiographic outcomes at 1 year (mITT population) Placebo+MTX Rituximab +MTX 2 × 1000 mg
Croatian: Tablica 13 Radiološki ishodi nakon 1 godine (prilagođena ITT populacija) Placebo + metotreksat
English: Respiratory, thoracic and mediastinal disorders bronchospasm4, respiratory disease, chest pain, dyspnoea, increased cough, rhinitis asthma, bronchiolitis obliterans, lung disorder, hypoxia interstitial lung disease7
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja bronhospazam4, bolest dišnog sustava, bol u prsnom košu, dispneja, pojačan kašalj, rinitis astma, obliterirajući bronhiolitis, plućni poremećaj, hipoksija intersticijska bolest pluća7
English: +myocardial infarction4 and 6, arrhythmia, +atrial fibrillation, tachycardia, +cardiac disorder
Croatian: aritmija, +fibrilacija atrija, tahikardija, +srčani poremećaj
English: For retreatment with Blitzima monotherapy for patients who have responded to previous treatment with Blitzima monotherapy for relapsed/refractory follicular lymphoma, the recommended dose is: 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for four weeks (see section 5.1).
Croatian: Kod ponovne primjene monoterapije lijekom Blitzima u bolesnika s relapsirajućim/refraktornim folikularnim limfomom koji su odgovorili na prethodno liječenje lijekom Blitzima u monoterapiji, preporučena doza iznosi 375 mg/m površine tijela, a primjenjuje se u obliku intravenske infuzije jedanput tjedno tijekom četiri tjedna (vidjeti dio 5.1).
English: LogRank p
Croatian: Stopa b
English: Although rituximab is not myelosuppressive in monotherapy, caution should be exercised when considering treatment of patients with neutrophils < 1.5 x 109/L and/or platelet counts < 75 x 109/L as clinical experience in this population is limited.
Croatian: Iako rituksimaba primijenjena u monoterapiji nema mijelosupresivan učinak, potreban je oprez kada se razmatra liječenje bolesnika s brojem neutrofila < 1,5 x 10
English: The recommended dose of Blitzima used as a maintenance treatment for patients with relapsed/refractory follicular lymphoma who have responded to induction treatment is: 375 mg/m2 body surface area once every 3 months (starting 3 months after the last dose of induction therapy) until disease progression or for a maximum period of two years (8 infusions in total).
Croatian: • Relapsirajući/refraktorni folikularni limfom Preporučena doza lijeka Blitzima u terapiji održavanja u bolesnika s relapsirajućim/refraktornim folikularnim limfomom koji su odgovorili na uvodno liječenje iznosi 375 mg/m površine tijela jedanput svaka 3 mjeseca (počevši 3 mjeseca nakon zadnje doze uvodne terapije) do progresije bolesti ili najdulje dvije godine (ukupno 8 infuzija).
English: Sodium chloride Tri-sodium citrate dihydrate Polysorbate 80
Croatian: 6.1 Popis pomoćnih tvari natrijev klorid natrijev citrat dihidrat polisorbat 80 voda za injekcije
English: You might get infections more easily during your treatment with Blitzima.
Croatian: Tijekom liječenja lijekom Blitzima možda ćete biti podložniji infekcijama.
English: Blitzima 500 mg concentrate for solution for infusion
Croatian: Blitzima 500 mg koncentrat za otopinu za infuziju
English: In a multicentre, single-arm trial, 58 patients with relapsed or chemoresistant low grade or follicular B cell NHL, who had achieved an objective clinical response to a prior course of rituximab, were re-treated with 375 mg/m2 of rituximab as intravenous infusion weekly for four doses.
Croatian: U multicentričnom nekomparativnom ispitivanju je 58 bolesnika s relapsirajućim ili kemorezistentnim B-staničnim ne-Hodgkinovim folikularnim limfomom ili limfomom niskog stupnja malignosti, u kojih je postignut očekivan klinički odgovor na prethodno liječenje rituksimabom, ponovno liječeno rituksimabom u dozi od 375 mg/m putem intravenske infuzije jedanput tjedno tijekom četiri tjedna.
English: Disease‐free survivala
Croatian: Preživljenje bez bolesti a
English: Adverse drug reaction rituximab + low-dose prednisone (n=38)
Croatian: Ritukximab niska doza prednizona (n 38)
English: Prednisone treatment was tapered and then kept at a low dose (approximately 5 mg per day) for at least 18 months after randomisation.
Croatian: Doza prednizona postupno se smanjivala, a potom održavala na niskoj razini (približno 5 mg na dan)
English: Table 4 Adverse drug reactions occurring in ≥ 5% of patients receiving rituximab for maintenance treatment of GPA and MPA, and at a higher frequency than the comparator group
Croatian: Tablica 4 Nuspojave koje su nastupile u ≥ 5% bolesnika koji su primali lijek rituksimab za terapiju održavanja GPA i MPA i koje su se javile s većom učestalošću nego u usporednoj skupini
English: Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients listed in section 6.1.
Croatian: Preosjetljivost na djelatnu tvar, mišje proteine ili neku od ostalih pomoćnih tvari navedenih u dijelu 6.1. Aktivne, teške infekcije (vidjeti dio 4.4).
English: You may be asked not to take these other medicines 12 hours before you are given Blitzima.
Croatian: Možda te lijekove nećete smjeti uzeti 12 sati prije primjene lijeka Blitzima zato što nekim bolesnicima može pasti krvni tlak tijekom primjene lijeka Blitzima.
English: Date of most recent infusion:
Croatian: Datum posljednje obnove odobrenja:
English: Blitzima is used for the treatment of granulomatosis with polyangiitis (formerly called Wegener's granulomatosis) or microscopic polyangiitis, taken in combination with corticosteroids.
Croatian: c) granulomatoze s poliangiitisom ili mikroskopskog poliangiitisa Blitzima se u kombinaciji s kortikosteroidima primjenjuje za poticanje remisije granulomatoze s poliangiitisom (ranije se zvala Wegenerova granulomatoza) i mikroskopskog poliangiitisa.
English: The recommended dose of Blitzima monotherapy used as induction treatment for adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy is: 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for 4 weeks.
Croatian: Preporučena doza lijeka Blitzima u monoterapiji kod uvodnog liječenja odraslih bolesnika oboljelih od folikularnog limfoma stadija III-IV koji su rezistentni na kemoterapiju ili su u drugom odnosno sljedećem relapsu nakon kemoterapije iznosi 375 mg/m2 površine tijela, a primjenjuje se u obliku intravenske infuzije jedanput tjedno tijekom četiri tjedna.
English: The mean Cmax (N=15) was 408 µg/mL (range, 97 - 764 µg/mL) after the fifth 500 mg/m2
Croatian: Prosječni Cmax (N = 15) nakon pete infuzije od 500 mg/m2 iznosio je 408 µg/ml (raspon 97-764 µg/ml), dok je prosječan terminalni poluvijek bio 32 dana (raspon 14-62 dana).
English: Clinical experience in non-Hodgkin's lymphoma and in chronic lymphocytic leukaemia
Croatian: Klinička iskustva u liječenju ne-Hodgkinova limfoma i kronične limfocitne leukemije Folikularni limfom
English: infusions separated by two weeks (on Day 1 and Day 15) followed by 500 mg IV every 6 months for 18 months) or azathioprine (administered orally at a dose of 2 mg/kg/day for 12 months, then 1.5 mg/kg/day for 6 months, and finally 1 mg/kg/day for 4 months (treatment discontinuation after these 22 months).
Croatian: Nakon postizanja remisije, a unutar najviše mjesec dana od primjene posljednje pulsne doze ciklofosfamida, bolesnici su bili randomizirani za primanje lijeka rituksimab (dvije i.v. infuzije od 500 mg u razmaku od dva tjedna [1. dana i 15. dana], a zatim 500 mg i.v. svakih 6 mjeseci tijekom 18 mjeseci) ili azatioprina (primijenjenog peroralno u dozi od 2 mg/kg na dan tijekom 12 mjeseci, zatim u dozi od 1,5 mg/kg na dan tijekom 6 mjeseci i na kraju u dozi od 1 mg/kg na dan tijekom 4 mjeseca [prekid liječenja nakon ta 22 mjeseca]).
English: Common Uncommon
Croatian: Obični pemfigus
English: Initial treatment, in combination with chemotherapy In an open-label randomised trial, a total of 322 previously untreated patients with follicular lymphoma were randomised to receive either CVP chemotherapy (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2 up to a maximum of 2 mg on day 1, and prednisolone 40 mg/m2/day on days 1-5) every 3 weeks for 8 cycles or rituximab 375 mg/m2 in combination with CVP (R-CVP).
Croatian: U otvorenom randomiziranom ispitivanju ukupno su 322 prethodno neliječena bolesnika s folikularnim limfomom slučajnim odabirom određena za primanje CVP kemoterapije (ciklofosfamid 750 mg/m2, vinkristin 1,4 mg/m do najviše 2 mg prvog dana liječenja, prednizolon 40 mg/m2/dan od prvog do petog dana liječenja) svaka 3 tjedna u 8 ciklusa liječenja, ili rituksimaba u dozi od 375 mg/m u kombinaciji s CVP kemoterapijom (R-CVP).
English: Blitzima is indicated in adults for the following indications:
Croatian: Blitzima je indicirana u odraslih u sljedećim indikacijama: Ne-Hodgkinov limfom (NHL)
English: Blitzima 100 mg concentrate for solution for infusion
Croatian: Blitzima 100 mg koncentrat za otopinu za infuziju
English: Blitzima is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.
Croatian: Blitzima je u kombinaciji s kemoterapijom indicirana u liječenju bolesnika oboljelih od folikularnog limfoma stadija III-IV koji prethodno nisu liječeni.
English: • heart failure
Croatian: Srčani poremećaji
English: Of
Croatian: a
English: General disorders and administratio n site conditions fever, chills, asthenia, headache tumour pain, flushing, malaise, cold syndrome, +fatigue, +shivering, +multi-organ failure4
Croatian: Opći poremećaji i reakcije na mjestu primjene vrućica, zimica, astenija, glavobolja bol u predjelu tumora, navale crvenila, opća slabost, sindrom prehlade, +umor, +drhtavica, +zatajenje više organa4
English: In a multicentre, single-arm trial, 37 patients with relapsed or chemoresistant, low grade or follicular B cell NHL received 375 mg/m2 of rituximab as intravenous infusion weekly for eight doses.
Croatian: U multicentričnom, nekomparativnom ispitivanju 37 bolesnika s relapsirajućim ili kemorezistentnim B-staničnim ne-Hodgkinovim folikularnim limfomom ili limfomom niskog stupnja malignosti primilo je rituksimab u dozi od 375 mg/m putem intravenske infuzije jedanput tjedno tijekom osam tjedana.
English: Log-Rank p value
Croatian: log-rang pvrijednost
English: Progression‐free Survival (PFS)
Croatian: Preživljenje bez progresije (PFS)
English: Product information
Croatian: FARMACEUTSKI PODACI
English: Blitzima is used for the treatment of patients with moderate to severe pemphigus vulgaris.
Croatian: Blitzima se primjenjuje za liječenje bolesnika s umjerenim do teškim običnim pemfigusom.
English: Overall response rate* chi-squared test p value odds ratio (95% CI)
Croatian: log-rang p-vrijednost omjer hazarda (95% CI) smanjenje rizika Stopa ukupnog odgovora* p-vrijednost iz hi-kvadrat testa omjer izgleda (95% CI) Stopa potpunog odgovora (CR/CRu)* p-vrijednost iz hi-kvadrat testa omjer izgleda (95% CI)
English: Influenza-like illness Oedema peripheral
Croatian: Opći poremećaji i reakcije na mjestu primjene periferni edem
English: PFS
Croatian: CR
English: heart failure4
Croatian: snižene razine IgGa4
English: Also do not breast-feed for 12 months after your last treatment with Blitzima.
Croatian: Ne smijete dojiti dijete tijekom liječenja lijekom Blitzima i još 12 mjeseci nakon posljednje primjene lijeka jer se Blitzima može izlučiti u majčino mlijeko.
English: Blitzima 500 mg concentrate for solution for infusion Rituximab
Croatian: Blitzima 500 mg koncentrat za otopinu za infuziju rituksimab
English: • If you are having Blitzima with chemotherapy Blitzima will be given to you on the same day as your chemotherapy.
Croatian: ako se liječite lijekom Blitzima u kombinaciji s kemoterapijom Lijek Blitzima primit ćete istoga dana kao i kemoterapiju, koja se obično daje do 8 puta u razmacima od 3 tjedna.
English: PATIENT ALERT CARD TEXT FOR NON-ONCOLOGY INDICATIONS Blitzima (Rituximab) Alert Card for patients with non-oncology diseases Why have I been given this card?
Croatian: Blitzima (rituksimab) kartica s upozorenjima za bolesnike s neonkološkim bolestima
English: • short term increase in the amount of some types of anti-bodies in the blood (called immunoglobulins - IgM), chemical disturbances in the blood caused by break-down of dying cancer cells
Croatian: Vrlo rijetke nuspojave (mogu se javiti u do 1 na 10 000 osoba): kratkotrajno povišenje količine nekih vrsta protutijela u krvi (imunoglobulina - IgM),
English: Blitzima 100 mg concentrate for solution for infusion Rituximab
Croatian: Blitzima 100 mg koncentrat za otopinu za infuziju rituksimab
English: Pneumocystis jirovecii pneumonia prophylaxis was required for all patients with CD4+ T-lymphocyte counts less than 250 per cubic millimeter.
Croatian: T-limfocita bio manji od 250/mm morali su primati profilaksu za pneumoniju koju uzrokuje
English: IgG levels
Croatian: IgG-a
English: In the pivotal trial, 166 patients with relapsed or chemoresistant low-grade or follicular B cell NHL received 375 mg/m2 of rituximab as an intravenous infusion once weekly for four weeks.
Croatian: Početno liječenje, jedanput tjedno tijekom 4 tjedna U pivotalnom je ispitivanju 166 bolesnika s relapsirajućim ili kemorezistentnim, nisko malignim ili folikularnim B-staničnim ne-Hodgkinovim limfomom primilo rituksimab u dozi od 375 mg/m putem intravenske infuzije jedanput tjedno tijekom četiri tjedna.
English: A small number of cases of hepatitis B reactivation, some with fatal outcome, have been reported in granulomatosis with polyangiitis and microscopic polyangiitis patients receiving rituximab in the postmarketing setting.
Croatian: U bolesnika s granulomatozom s poliangiitisom i mikroskopskim poliangiitisom koji su primali rituksimab nakon njegova stavljanja u promet prijavljen je malen broj slučajeva reaktivacije hepatitisa B, ponekad sa smrtnim ishodom.
English: Blitzima
Croatian: KLL-a
English: d)
Croatian: PR
English: Patient information
Croatian: Informacije o lijeku
English: Studies in previously untreated and relapsed/refractory CLL have established that in up to 25% of patients treated with R-FC neutropenia was prolonged (defined as neutrophil count remaining below 1x109/L between day 24 and 42 after the last dose) or occurred with a late onset (defined as neutrophil count below 1x109/L later than 42 days after last dose in patients with no previous prolonged neutropenia or who recovered prior to day 42) following treatment with rituximab plus FC.
Croatian: Ispitivanjima prethodno neliječenog i relapsirajućeg/refraktornog KLL-a utvrdilo se da je u do 25 % bolesnika koji su primali R-FC neutropenija bila produljena (definirano kao broj neutrofila koji je ostao niži od 1 x 10
English: CHVP-IFN, R-CHVPIFN, 175
Croatian: R-CHVP-IFN:
English: Patient subpopulations - rituximab monotherapy
Croatian: Podskupine bolesnika - monoterapija rituksimabom Stariji bolesnici (≥ 65 godina):
English: % SF‐36 MHS MCID † Outcome at 24 weeks
Croatian: Srednja vrijednost promjene SF-36 MHS % bolesnika sa SF-36 MHS MCID
English: immunosuppressive therapy and/or chemotherapy.
Croatian: Početno liječenje u kombinaciji s kemoterapijom
English: Metabolism hyperglycaemia
Croatian: Poremećaji metabolizma i prehrane hiperkalijemija
English: Hyperkalaemia
Croatian: Hematološke nuspojave
English: CELLTRION Inc.,
Croatian: Vistor hf.
English: Corbilta with food and drink
Croatian: Corbilta s hranom i pićem
English: Do not stop taking Corbilta unless your doctor tells you to.
Croatian: Corbiltu nemojte prestati uzimati osim ako Vam to ne kaže Vaš liječnik.
English: Other medicines and Corbilta
Croatian: Drugi lijekovi i Corbilta
English: You should be aware that Corbilta may make these reactions worse.
Croatian: Morate biti svjesni da Corbilta te reakcije može pogoršati.
English: For adults and elderly: - Your doctor will tell you exactly how many tablets of Corbilta to take each day.
Croatian: Odrasli i starije osobe: - Vaš liječnik će odrediti točno koliko tableta Corbilte trebate uzeti svaki dan.
English: Date of first authorisation: 11 November 2013 Date of latest renewal: 8 June 2018
Croatian: Datum posljednje obnove odobrenja: 8. lipnja 2018.
English: Corbilta should not be used during pregnancy unless the benefits for the mother outweigh the possible risks to the foetus.
Croatian: Corbilta se ne smije primjenjivati tijekom trudnoće, osim ako je korist za majku veća od mogućih rizika za fetus.
English: Therefore, do not take Corbilta and iron supplements at the same time.
Croatian: Stoga ne uzimajte istodobno Corbiltu i preparate željeza.
English: Experience with Corbilta in patients under 18 years is limited.
Croatian: Iskustvo s Corbiltom u bolesnika mlađih od 18 godina je ograničeno.
English: If you take more Corbilta than you should
Croatian: Ako uzmete više Corbilte nego što ste trebali
English: Paediatric population: The safety and efficacy of Corbilta in children aged below 18 years have not been established.
Croatian: Pedijatrijska populacija: sigurnost i djelotvornost Corbilte u djece mlađe od 18 godina nisu ustanovljene.
English: Corbilta may be taken with or without food.
Croatian: Corbilta se može uzimati sa ili bez hrane.
English: Your doctor may take some regular laboratory tests during a long term treatment with Corbilta.
Croatian: Vaš će Vam liječnik možda napraviti neke redovite laboratorijske pretrage tijekom dugotrajnog liječenja Corbiltom.
English: Therefore, Corbilta and iron preparations should be taken at least 2-3 hours apart (see section 4.8).
Croatian: Stoga razmak između uzimanja Corbilte i preparata željeza mora iznositi najmanje 2-3 sata (vidjeti dio 4.8).
English: It may therefore be necessary, particularly in patients with dyskinesia, to reduce levodopa dose by 10-30% within the first days to first weeks after initiating Corbilta treatment.
Croatian: Stoga može biti potrebno, posebno kod bolesnika s diskinezijom, smanjiti dozu levodope za 10-30% unutar prvih nekoliko dana ili tjedana po započinjanju liječenja Corbiltom.
English: Pyridoxine, however, is not effective in reversing the actions of Corbilta.
Croatian: Piridoksin, međutim, nije učinkovit u suzbijanju djelovanja Corbilte.
English: Therefore, the use of Corbilta in children or adolescents is not recommended.
Croatian: Stoga se primjena Corbilte u djece ili adolescenata ne preporučuje.
English: If you must undergo surgery, please tell your doctor that you are using Corbilta.
Croatian: Ako morate na kirurški zahvat, obavijestite svog liječnika da uzimate Corbiltu.
English: - All patients treated with Corbilta should be monitored carefully for the development of mental changes, depression with suicidal tendencies, and other serious antisocial behaviour.
Croatian: - Sve bolesnike liječene Corbiltom treba pažljivo pratiti glede razvoja mentalnih promjena, depresije sa suicidalnim tendencijama i drugog teškog antisocijalnog ponašanja.
English: Patients taking these medicinal products with Corbilta should be carefully observed for loss of therapeutic response.
Croatian: Bolesnike koji uzimaju ove lijekove s Corbiltom mora se pažljivo pratiti radi gubitka terapijskog odgovora.
English: Talk to your doctor or pharmacist if you think the effect of Corbilta is too strong or too weak, or if you experience possible side effects.
Croatian: Razgovarajte sa svojim liječnikom ili ljekarnikom ako mislite da je učinak Corbilte prejak ili preslab ili ako doživite moguće nuspojave.